Performance of the VERSANT (R) HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes
Derdelinckx, Inge; Van Laethem, Kristel; Maes, Baertet al.
2003 • In FEMS Immunology and Medical Microbiology, 39 (2), p. 119-124
human immunodeficiency virus type 1; resistance testing; subtypes; line probe assay
Abstract :
[en] In this study we evaluated the performance of the VERSANT((R)) HIV-1 Resistance Assays (LiPA) in detecting drug resistance in therapy-naive HIV-infected patients diagnosed in Belgium in 2000. We compared the results with population sequencing and found concordance to be in line with previous studies in treatment-experienced patients (86.87% for reverse transcriptase (RT); 92.77% for protease (PRO)). Discordance was mainly due to indeterminate reactions on LiPA (8.45% for RT; 6.85% for PRO) and minor discordances (4.13% for RT; 0.25% for PRO). Major discordances were rare (0.46% for RT; 0.12% for PRO). Indeterminate reactions were significantly associated with strains belonging to non-B subtypes. (C) 2003 Federation of European Microbiological Societies. Published by Elsevier B.V.. All rights reserved.
Disciplines :
Immunology & infectious disease
Author, co-author :
Derdelinckx, Inge
Van Laethem, Kristel
Maes, Baert
Schrooten, Yoeri
De Schouwer, Kirsten
De Wit, Stéphane
Fransen, Katrien
Garcia Ribas, Sergio
Moutschen, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Immunopathologie - Transplantation
Vaira, Dolorès ; Centre Hospitalier Universitaire de Liège - CHU > Immuno-hématologie
Performance of the VERSANT (R) HIV-1 Resistance Assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes
Yeni P., Hammer S.M., Carpenter C.C.J., Cooper D.A., Fischl M.A., Gatell J.M., Gazzard B.G., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Saag M.S., Schlechter M., Schooley R.T., Thompson M.A., Vella S., Volberding P.A. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 288:2002;222-235.
Hirsch M.S., Brun-Vezinet F., D'Aquila R.T., Hammer S.M., Johnson V.A., Kuritzkes D.R., Loveday C., Mellors J.W., Clotet B., Conway B., Demeter L.M., Vella S., Jacobsen D.M., Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel [see comments]. JAMA. 283:2000;2417-2426.
The Euro Guidelines Group for HIV resistance (2001) Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 15, 309-320.
Vandamme A.-M., Houyez F., Bànhegyi D., Clotet B., De Schrijver G., De Smet K.A.L., Hall W.W., Harrigan R., Hellmann N., Hertogs K., Holtzer C., Larder B., Pillay D., Race E., Schmit J.-C., Schuurman R., Shulse E., Sönnerborg A., Miller V. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antivir. Ther. 6:2001;21-40.
Rapport 2002 sous la direction du Professeur J.F. Delfraissy (2002) Prise en charge des personnes infectées par le VIH. Recommandations du groupe d'experts. Médecine-Sciences, Flammarion, Paris.
Van Laethem K., Van Vaerenbergh K., Schmit J.-C., Sprecher S., Hermans P., De Vroey V., Schuurman R., Harrer T., Witvrouw M., Van Wijngaerden E., Stuyver L., Van Ranst M., Desmyter J., De Clercq E., Vandamme A.-M. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. JAIDS. 22:1999;107-118.
Stuyver L., Wyseur A., Rombout A., Louwagie J., Scarcez T., Verhofstede C., Rimland D., Schinazi R.F., Rossau R. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. 41:1997;284-291.
Grant R.M., Hecht F.M., Warmerdam M., Liu L., Liegler T., Petropoulos C.J., Hellmann N.S., Chesney M., Busch M.P., Kahn J.O. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA. 288:2002;181-188.
Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., Koup R.A., Mellors J.W., Connick E., Conway B., Kilby M., Wang L., Whitcomb J.M., Hellmann N.S., Richman D.D. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:2002;385-394.
Snoeck J., Van Dooren S., Van Laethem K., Derdelinckx I., Van Wijngaerden E., De Clercq E., Vandamme A.-M. Prevalence and origin of HIV-1 group M subtypes among patients attending a Belgian hospital in 1999. Virus Res. 85:2002;95-108.
Fontaine E., Riva C., Peeters M., Schmit J.-C., Delaporte E., Van Laethem K., Van Vaerenbergh K., Snoeck J., Van Wijngaerden E., De Clercq E., Van Ranst M., Vandamme A.-M. Evaluation of two commercial kits for the detection of genotypic drug-resistance on a panel of human immunodeficiency virus type-1 subtypes A-J. JAIDS. 28:2001;254-258.
Jenny-Avital E.R., Beatrice S.T. Erroneously low or undetectable plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid load, determined by polymerase chain reaction, in West African and American patients with non-B subtype HIV-1 infection. Clin. Infect. Dis. 32:2001;1227-1230.
Fransen K., Buve A., Nkengasong J.N., Laga M., van der Groen G. Longstanding presence of non-B subtypes in Belgians. Lancet. 347:1996;1403.
Vandamme, A.-M., Witvrouw, M., Pannecouque, C., Balzarini, J., Van Laethem, K., Schmit, J.-C., Desmyter, J. and De Clercq, E. (2000) Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In: Methods in Molecular Medicine (Kinchington, D. and Schinazi, R.F., Eds.), pp. 223-258. Humana Press Inc., Totowa, New York.
Descamps D., Calvez V., Collin G., Cécille G., Apetrei C., Damond F., Katlama C., Matheron S., Huraux J.-M., Brun-Vézinet F. Line Probe Assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis. J. Clin. Microbiol. 36:1998;2143-2145.
Schmit J.-C., Ruiz L., Stuyver L., Van Laethem K., Vanderlinden I., Puig T., Rossau R., Desmyter J., De Clercq E., Clotet B., Vandamme A.-M. Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance. J. Virol. Methods. 73:1998;82.
Puchhammer-Stöckl E., Schmied B., Mandl C.W., Vetter N., Heinz F.X. Comparison of Line Probe Assay (LiPA) and sequence analysis for detection of HIV-1 drug resistance. J. Med. Virol. 57:1999;283-289.
Koch N., Yahi N., Colson P., Fantini J., Tamalet C. Genetic polymorphism near HIV-1 reverse transcriptase resistance-associated codons is a major obstacle for the line probe assay as an alternative method to sequence analysis. J. Virol. Methods. 80:1999;25-31.
Servais J., Lambert C., Fontaine E., Plesseria J.M., Robert I., Arendt V., Staub T., Schneider F., Hemmer R., Burtonboy G., Schmit J.C. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J. Clin. Microbiol. 39:2001;454-459.
Stürmer M., Morgenstern B., Staszewski S., Doerr H.W. Evaluation of the LiPA HIV-1 RT assay version 1: comparison of sequence and hybridization based on genotyping systems. J. Clin. Virol. 25:2002;S65-S72.
Louwagie J., McCutchan F.E., Peeters M., Brennan T.P., Sanders-Buell E., Eddy G.A., van der Groen G., Fransen K., Gershy-Damet G.-M., Deleys R., Burke D.S. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS. 7:1993;769-780.